STAT1, the primary transcription factor activated by IFN, has been studied as a more sensitive and reliable biomarker than other pathway-specific activated STATs and monitored in multiple sclerosis patients after IFN-β administration (Gavasso et al., 2014). The gene discussed is STAT1; the disease is multiple sclerosis.